- Home
- NEWT vs FHTX Comparison
NEWT vs FHTX Comparison
Compare NEWT & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWT
- FHTX
- Stock Information
- Founded
- NEWT 1998
- FHTX 2015
- Country
- NEWT United States
- FHTX United States
- Employees
- NEWT N/A
- FHTX N/A
- Industry
- NEWT Major Banks
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- NEWT Finance
- FHTX Health Care
- Exchange
- NEWT Nasdaq
- FHTX Nasdaq
- Market Cap
- NEWT 342.5M
- FHTX 517.9M
- IPO Year
- NEWT N/A
- FHTX 2020
- Fundamental
- Price
- NEWT $13.53
- FHTX $7.55
- Analyst Decision
- NEWT Hold
- FHTX Strong Buy
- Analyst Count
- NEWT 3
- FHTX 5
- Target Price
- NEWT $12.33
- FHTX $16.00
- AVG Volume (30 Days)
- NEWT 158.0K
- FHTX 135.3K
- Earning Date
- NEWT 11-06-2024
- FHTX 11-04-2024
- Dividend Yield
- NEWT 5.61%
- FHTX N/A
- EPS Growth
- NEWT 18.20
- FHTX N/A
- EPS
- NEWT 1.66
- FHTX N/A
- Revenue
- NEWT $301,043,000.00
- FHTX $35,185,000.00
- Revenue This Year
- NEWT N/A
- FHTX N/A
- Revenue Next Year
- NEWT $6.30
- FHTX $15.40
- P/E Ratio
- NEWT $8.10
- FHTX N/A
- Revenue Growth
- NEWT 54.13
- FHTX 61.95
- 52 Week Low
- NEWT $10.07
- FHTX $2.70
- 52 Week High
- NEWT $15.75
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- NEWT 65.25
- FHTX 45.26
- Support Level
- NEWT $12.34
- FHTX $7.24
- Resistance Level
- NEWT $13.85
- FHTX $8.35
- Average True Range (ATR)
- NEWT 0.34
- FHTX 0.54
- MACD
- NEWT 0.10
- FHTX -0.06
- Stochastic Oscillator
- NEWT 82.89
- FHTX 43.20
About NEWT NewtekOne Inc.
NewtekOne Inc is a financial holding company engaged in providing financial solutions, It has developed a financial and technology-based business model that enables itself to acquire and process its clients in a very cost-effective manner. This capability is supported in large part by NewTracker, its patented prospect management technology software, that will allow NewtekOne clients to easily interact with NewtekOne subject matter experts in the areas of Banking, Lending, Payments, Technology, Payroll, and Insurance. It offers NewtekOne's clients a single online dashboard to access all of NewtekOne's business and financial solutions. It has four reportable segments Banking, Technology, NSBF, and Payments.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.